Autolus Therapeutics plc (AUTL) Q2 2026 Earnings Call Transcript

Autolus Therapeutics NASDAQ: AUTL reported second-quarter 2026 net product revenue of $45.7 million

Autolus Therapeutics (NASDAQ:AUTL) affirms FY2026 sales outlook from $140.000 million-$150.000 milli

Autolus Therapeutics (NASDAQ:AUTL) reported quarterly losses of $(0.15) per share which beat the ana

LONDON and GAITHERSBURG, Md., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AU

HC Wainwright & Co. analyst Emily Bodnar reiterates Autolus Therapeutics (NASDAQ:AUTL) with a

Gainers Universe Pharmaceuticals (NASDAQ:UPC) shares increased by 108.5% to $6.59 during Monday&#39

Dow Jones index gained 600 points, CNH Industrial rose 16% after reporting better-than-expected Q2 r

Company reports preliminary Q2 2026 AUCATZYL net product revenue of approximately $45 million and gr

Company reports preliminary Q2 2026 AUCATZYL net product revenue of approximately $45 million and gr

Autolus Therapeutics maintains a Buy rating, driven by ongoing execution in CAR T-cell therapy, espe

Oncology innovation is reshaping cancer care as AI, immunotherapy and targeted therapies fuel pipeli

LONDON & GAITHERSBURG, Md., July 01, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL

LONDON and GAITHERSBURG, Md., June 25, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AU

LONDON and GAITHERSBURG, Md., June 12, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AU

After losing some value lately, a hammer chart pattern has been formed for Autolus Therapeutics (AUT

Autolus Therapeutics PLC Sponsored ADR (AUTL) reached a significant support level, and could be a go

LONDON and GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUT

LONDON and GAITHERSBURG, Md., May 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUT

TOYO shares rose 13.7% after beating earnings expectations. Other top gainers include JLHL, RAMP, HI

Autolus Therapeutics plc (AUTL) Q1 2026 Earnings Call Transcript

HC Wainwright & Co. analyst Emily Bodnar maintains Autolus Therapeutics (NASDAQ:AUTL) with a

Autolus Therapeutics NASDAQ: AUTL reported higher first-quarter 2026 product revenue and said its co

Autolus Therapeutics (NASDAQ:AUTL) sees FY2026 sales of $120.000 million-$135.000 million vs $130.06

Autolus Therapeutics (NASDAQ:AUTL) reported quarterly losses of $(0.27) per share which met the anal

AUCATZYL® (obecabtagene autoleucel; obe-cel) net product revenue of $26.2 million for the first quar

LONDON and GAITHERSBURG, Md., May 05, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUT

Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, ma

Initiative focused on driving gross profit margin and path to profitability for the ALL business Com

LONDON and GAITHERSBURG, Md., April 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: A

Autolus Therapeutics (NASDAQ: AUTL) hosted an investor event focused on its acute lymphoblastic leuk

Needham analyst Gil Blum reiterates Autolus Therapeutics (NASDAQ:AUTL) with a Buy and maintains $

Autolus Therapeutics plc (AUTL) Discusses Advances in B-cell Precursor Acute Lymphoblastic Leukemia

LONDON and GAITHERSBURG, Md., April 07, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: A

US stock futures up, Nasdaq 100 gains 100 pts. Service Properties Trust (SVC) drops 4% in pre-market

Mizuho analyst Salim Syed maintains Autolus Therapeutics (NASDAQ:AUTL) with a Outperform and lowe

Needham analyst Gil Blum reiterates Autolus Therapeutics (NASDAQ:AUTL) with a Buy and maintains $

Autolus Therapeutics (NASDAQ:AUTL) reported quarterly losses of $(0.34) per share which missed the a

HC Wainwright & Co. analyst Emily Bodnar initiates coverage on Autolus Therapeutics (NASDAQ:A

FDA lifts REMS for approved CAR-T therapies, easing hospital restrictions and signaling broader futu